Company intelligence / Profile preview

DISIT Biotech

Ownership: Private
Development stage: Preclinical

Overview

DISIT Biotech is developing peptide-based therapies targeting TGF‑β inhibition for the treatment of radiation-induced tissue damage and complications in oncology, with a particular emphasis on breast cancer. Their lead compound is "Disitertide," which has demonstrated efficacy in preclinical models and is progressing through early-stage clinical development

Therapeutic areas: Oncology
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

disitertide

Pre-clinical

Indications: Radiation-induced fibrosis, Liver fibrosis

Partnerships

Pink Knot Project collaboration for breast cancer awareness

Beyond the preview

Go deeper on DISIT Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DISIT Biotech.

Explore the full profile